Novartis accelerates digital transformation with Amazon collaboration

Novartis has entered into a multi-year collaboration with Amazon Web Services (AWS) to reimagine its core pharmaceutical manufacturing, supply chain and delivery options using cloud services.

Core to this collaboration is the creation of Novartis ‘Insight Centers’ that provide real-time visibility across its network of manufacturing operations and distribution centres.

Building on the success of its trial operations centre SENSE, these ‘Insight Centers’ can enable manufacturing and planning teams to better forecast and track production lines, detect potential bottlenecks and then make adjustment recommendations to improve accuracy.

Using AWS, Novartis can collect inventory, quality, and production data across its network and apply AWS Internet of Things (IoT), analytics, and machine learning (ML) services to gain greater visibility and help drive efficiencies.

By centralising this data, Novartis data scientists can also experiment with new optimisation models to help ramp up the production of innovative, personalized treatments that are more complex to make.

In addition, Novartis plans to use AWS IoT services to augment and improve visual inspections of its manufacturing sites by generating images that can be analysed using computer vision algorithms to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders.

With this real-time data, Novartis associates can be better equipped to make data-based decisions that help ensure medicines are efficiently produced and distributed to nearly 1 billion patients in 155 countries around the world.

“Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster,” said Bertrand Bodson, Chief Digital Officer at Novartis.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news